11 нояб. 2023 г. · In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial, we tested the hypothesis that the ...

Информация об этой странице недоступна. ·

12 сент. 2024 г. · The SELECT trial extends the findings of SUSTAIN-6 and other GLP-1 RA trials, which have demonstrated CV benefit in DM, to this increased-risk ...

24 авг. 2024 г. · We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes.

14 дек. 2023 г. · Methods: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or ...

13 мая 2024 г. · In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with ...

3 нояб. 2024 г. · New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease ...

11 нояб. 2023 г. · In a multicenter, double-blind, randomized, placebo-controlled, event-driven supe- riority trial, we enrolled patients 45 years of age or ...

24 авг. 2024 г. · In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure ...

13 мая 2024 г. · “SELECT was a well conducted randomised controlled trial which looked at the effects of semaglutide on cardiovascular disease events in people ...